Company profile
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ: CVKD · Healthcare · Biotechnology
PublicHQ Ponte Vedra, FLCIK 0001937993Reports USD
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH 23DQ —GM —SS 22
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$13.2M
Employees
5
as of 2026-08-22
Market cap
$5.7M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$13.2M-$13.2M2025
Operating income-$13.5M-$13.5M2025
Total assets$4.3M$4.3M2025
Liabilities$1.6M$1.6M2025
Equity$2.7M$2.7M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cadrenal Therapeutics, Inc. Common Stock’s financial profile?
Cadrenal Therapeutics, Inc. Common Stock earned -$13.2M in FY2025 net income.
Peers · Healthcare
Medicus Pharma Ltd. Common Stock——Adial Pharmaceuticals, Inc.——Alzamend Neuro Inc——CordovaCann Corp.——Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst——Qscreen Ai Inc.——Key facts
CEOQuang X. Pham
SectorHealthcare
IndustryBiotechnology
HeadquartersPonte Vedra, FL
ExchangeNASDAQ: CVKD
Employees5
IPO date2023-01-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.